These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Weeks BS, Nomizu M, Otaka A, Weston CA, Okusu A, Tamamura H, Yamamoto N, Fujii N. Biochem Biophys Res Commun; 1995 Oct 13; 215(2):626-31. PubMed ID: 7488001 [Abstract] [Full Text] [Related]
7. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II). Otaka A, Tamamura H, Terakawa Y, Masuda M, Koide T, Murakami T, Nakashima H, Matsuzaki K, Miyajima K, Ibuka T. Biol Pharm Bull; 1994 Dec 13; 17(12):1669-72. PubMed ID: 7735216 [Abstract] [Full Text] [Related]
8. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. Xu Y, Tamamura H, Arakaki R, Nakashima H, Zhang X, Fujii N, Uchiyama T, Hattori T. AIDS Res Hum Retroviruses; 1999 Mar 20; 15(5):419-27. PubMed ID: 10195751 [Abstract] [Full Text] [Related]
9. Structure-activity relationships of an anti-HIV peptide, T22. Tamamura H, Murakami T, Masuda M, Otaka A, Takada W, Ibuka T, Nakashima H, Waki M, Matsumoto A, Yamamoto N. Biochem Biophys Res Commun; 1994 Dec 30; 205(3):1729-35. PubMed ID: 7811258 [Abstract] [Full Text] [Related]
10. An anti-HIV peptide, T22, forms a highly active complex with Zn(II). Tamamura H, Otaka A, Murakami T, Ibuka T, Sakano K, Waki M, Matsumoto A, Yamamoto N, Fujii N. Biochem Biophys Res Commun; 1996 Dec 13; 229(2):648-52. PubMed ID: 8954952 [Abstract] [Full Text] [Related]
11. Lymphocytes and promonocytes attach to the synthetic [Tyr5,12, Lys7]- polyphemusin II peptide. Weeks BS, Nomizu M, Otaka A, Weston CA, Okusu A, Tamamura H, Matsumoto A, Yamamoto N, Fujii N. Biochem Biophys Res Commun; 1994 Jul 15; 202(1):470-5. PubMed ID: 8037749 [Abstract] [Full Text] [Related]
16. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T. J Exp Med; 1997 Oct 20; 186(8):1389-93. PubMed ID: 9334379 [Abstract] [Full Text] [Related]
18. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. Dey B, Lerner DL, Lusso P, Boyd MR, Elder JH, Berger EA. J Virol; 2000 May 20; 74(10):4562-9. PubMed ID: 10775592 [Abstract] [Full Text] [Related]
19. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion. Berger EA, Lifson JD, Eiden LE. Proc Natl Acad Sci U S A; 1991 Sep 15; 88(18):8082-6. PubMed ID: 1896455 [Abstract] [Full Text] [Related]
20. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step. Barbouche R, Decroly E, Kieny MP, Fenouillet E. Virology; 2000 Jul 20; 273(1):169-77. PubMed ID: 10891419 [Abstract] [Full Text] [Related] Page: [Next] [New Search]